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Purpose	
Coronavirus disease 2019 (COVID-19) presents with a spectrum of disease severity, the most serious
cases requiring intensive care. Echocardiography is a front-line tool in evaluating cardiovascular
complications of COVID-19 in the intensive care unit (ICU); we analyzed transthoracic echocardiograms
obtained from this patient population with state-of-the-art ultrasound technology.
Methods	All patients with COVID-19 requiring ICU admission on whom a transthoracic echocardiogram was
obtained were included in the study. Focused transthoracic protocols were performed by experienced
sonographers. Echocardiographic variables, including speckle-tracking echocardiography, were
collected and analyzed. Clinical information was obtained from the electronic medical record. Patients
were followed until discharge.
Results 	Of 52 total patients (mean age: 59.9 ± 11.6 years), 59.6% were male and 15 (29%) had known
prior cardiac disease. Cardiac complications identified on echocardiography were prevalent,
occurring in 55.7% of patients. Patients with known prior cardiac disease were more likely to have
new or worsening left ventricular dysfunction. Right ventricular dysfunction was the most common
abnormality (assessed qualitatively in 18 cases and with advanced echocardiographic methods in
34 cases). Known prior cardiac disease, right ventricular enlargement, and pulmonary hypertension
were significantly associated with morbidity and mortality.
Conclusions	Patients requiring intensive care for COVID-19 face significant morbidity and mortality, and cardiac
complications occur in the majority of patients admitted to the ICU with COVID-19. Those with known
prior cardiac disease fare worse, and other echocardiographic findings (right ventricular enlargement,
pulmonary hypertension) are also associated with worse outcomes. State-of-the-art echocardiography
performed by experienced sonographers can be critical to identifying cardiac complications and guiding
ICU strategy. (J Patient Cent Res Rev. 2021;8:68-76.)
Keywords	coronavirus; COVID-19; echocardiography; left ventricle; right ventricle; intensive care unit

C

oronavirus disease 2019 (COVID-19), the disease
caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), encompasses
myriad clinical presentations. In some patients, it is a mild
respiratory tract infection; in others, it is a debilitating
multisystem inflammatory illness that requires prolonged
care in the intensive care unit (ICU). Cardiac complications
of COVID-19 have been documented in case series and
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case reports since this virus first presented in human hosts
in late 2019.1-5 Different clinical presentations, including
elevated troponin, myocarditis, myopericarditis, and
acute coronary syndrome, have been seen in patients
without known prior cardiac disease. Preexisting cardiac
disease has been demonstrated to be a significant risk
factor for morbidity and mortality in patients who
contract COVID-19.6 Recent literature also has shown
the importance of right ventricular (RV) function in
predicting morbidity and mortality in hospitalized
patients with COVID-19.7,8
Echocardiography is a front-line tool for evaluation
of cardiovascular complications of COVID-19. It is
especially valuable in patients admitted to the ICU, as
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echocardiography can be performed with ease at the
bedside. Yet, most published studies used point-of-care
ultrasound to evaluate patients with COVID-19 due to
concerns about staff safety and machine contamination.
There is no study to date that has comprehensively
evaluated echocardiographic findings specifically of
patients admitted to the ICU with COVID-19, stratified
by known prior cardiac disease.
We sought to describe the echocardiographic
characteristics of patients presenting with COVID-19 who
underwent transthoracic echocardiography (TTE) during
their ICU stay and to evaluate potential echocardiographic
predictors of morbidity and mortality.

METHODS

We included all patients admitted to any of our medical
center’s designated “COVID ICUs” from March to
May 2020. Patients were diagnosed with COVID-19
(via positive SARS-CoV-2 polymerase chain reaction
test from nasopharyngeal swab) and had at least 1 TTE
performed during hospitalization. All included patients
had a discharge status (alive and discharged home, dead,
or discharged to a long-term care facility). The study was
approved by the local institutional review board, and
informed consent was waived.
The protocol for TTE was optimized to prioritize the
most advanced echocardiographic imaging while
ensuring the highest level of protection for the cardiac
sonographer. All TTEs were performed at the bedside
using the GE Vivid E95 system (GE Healthcare),
which was stored in the designated COVID ICU.
Keyboard and ultrasound transducer covers were used
(Figure 1A). A dedicated group of experienced cardiac
sonographers donned full personal protective equipment
as per hospital guidelines (N95 mask, face shield,
disposable gown, gloves, hair covers, and shoe covers)
and performed focused and detailed TTEs (Figure 1B).
These sonographers completed hospital training in
procedures for donning and doffing personal protection
equipment. Measurements were performed offline, not
within the patient’s room, to limit time of direct patient
exposure. TTE was performed in either the supine or
prone position using a focused protocol encompassing
all advanced echocardiographic methods. For proned
patients, attempts were made to perform TTE in supine
position, if possible. Details of this focused ICU TTE
protocol for COVID-19 have been published.9
All measurements were performed in accordance with
American Society of Echocardiography guidelines.10 Left
ventricular ejection fraction (LVEF) was calculated using
the biplane Simpson’s method. In patients with adequate
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Figure 1. Protection of sonographers. A: Protective
equipment for the echocardiography machine includes
a keyboard cover, transducer cover, and single-use gel.
B: Personal protective equipment for sonographers
includes an N95 mask, a face shield, a hair cover,
shoe covers, a disposable gown, and gloves.

image quality for speckle-tracking echocardiography,
peak left ventricular (LV) global longitudinal strain
(GLS) and RV GLS were performed. LV GLS was
obtained using standard apical 2-, 3-, and 4-chamber
views at frame rates of >60 frames per second. RV GLS
was performed by tracing the RV endocardial border,
then manually averaging 3 segments of RV free wall in
an RV-focused apical view at frame rates of >60 frames
per second. If available, echocardiograms performed
pre-COVID illness also were included in the analysis for
serial comparison.
The electronic medical record (Epic Systems
Corporation) was queried for demographic variables,
comorbidities, laboratory results, complications, and
details of COVID-related hospitalizations. Based on
clinical and echocardiographic data, patients with known
cardiomyopathy or coronary disease were grouped
into the “known prior cardiac disease” category; all
remaining patients were grouped into the “no known
prior cardiac disease” category.
Statistical Analysis

Categorical variables were summarized as counts and
proportions. Continuous variables were summarized
using mean and standard deviation (SD) or median
and interquartile range (IQR) if not assumed to be
normally distributed. Proportions were compared across
the aforedescribed groups using chi-squared test and
means using Student’s t-test (or their nonparametric
equivalents if normality assumption was not fulfilled).
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Statistical significance was defined as a two-sided
P-value of <0.05. All analyses were performed using
Stata 15 software (StataCorp LLC).

RESULTS

Clinical characteristics of 52 patients with COVID-19
admitted to the ICU are listed in Table 1. In this cohort,
mean age was 59.9 (SD: 11.6) years, median body mass
index was 31.7 kg/m2 (IQR: 26.4, 36.3), and 31 (60%)
patients were men. Our population was racially and
ethnically diverse. Common comorbidities included
obesity (n=27, 52%), hypertension (n=36, 69%), and
dyslipidemia (n=35, 67%).
The indication for ICU admission was acute respiratory
failure in 96% of cases (n=50), and 38 (73%) required
endotracheal intubation. Hemodynamic instability was
the primary indication for ICU admission in the remaining
2 cases (both were noted to have severe LV systolic
dysfunction). Patients had evidence of severe inflammation,
as noted by the following biomarkers: 70% (n=35) had
elevated D-dimer; 71% (n=37) had elevated ferritin; and
96% (n=47) had elevated C-reactive protein. The mean
Sequential Organ Failure Assessment score on ICU
admission was 5.7 (SD: 3.0). Proning strategy was part
of routine ICU care and was used in 45 (87%) cases. The
most common ICU complication was respiratory failure
(48% developed acute respiratory distress syndrome, the
remainder had severe bilateral pneumonia). There were
3 documented cases with thromboembolic complications
(deep venous thrombosis, pulmonary embolism, and
embolic cerebrovascular incident).
There were 15 (29%) patients with known prior cardiac
disease, some with multiple cardiac conditions — 4
(8%) had known LV systolic dysfunction, 4 (8%) had
moderate/severe pulmonary hypertension, 2 (4%) had
prior RV dysfunction, 9 (17%) had obstructive coronary
artery disease, 4 (8%) had heart failure with preserved
ejection fraction, 2 (4%) had prior heart transplantation,
1 had preexisting severe mitral regurgitation, and 1 had
prior moderate aortic stenosis.
All 52 TTEs were performed at the bedside, and 26
(50%) patients were intubated at the time of procedure.
Fewer than 5 TTEs were done in the prone position, thus,
not enough for statistical comparison with TTEs done
in the supine position. The majority had TTE performed
within 48 hours before and after ICU admission. The
mean TTE procedure time was 15.6 (SD: 5.7) minutes,
and the mean number of video clips obtained was 45
(SD: 13.2). All echocardiograms were diagnostic of the
clinical question, and the predominant indication was
evaluation of LV and RV systolic function.
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Table 1. Clinical Characteristics of Patients (N=52)
Variable
Age in years
18–39 years
40–49 years
50–59 years
60–69 years
70–79 years
80+ years
Race/Ethnicity
Hispanic
Non-Hispanic White
Black
Other
Male sex
Tobacco abuse
Obesity (BMI of >30 kg/m2)
Atrial fibrillation/Atrial flutter
Chronic obstructive pulmonary disease
Coronary artery disease
Diabetes
Dyslipidemia
Heart failure
Hypertension
Cancer
Known prior cardiac disease

Prevalence
59.9 (11.6)
3 (6%)
8 (15%)
13 (25%)
18 (35%)
8 (15%)
2 (4%)
18 (35%)
15 (29%)
13 (25%)
6 (12%)
31 (60%)
22 (33%)
27 (52%)
6 (12%)
5 (10%)
9 (17%)
19 (37%)
35 (67%)
11 (21%)
36 (69%)
10 (19%)
15 (29%)

Laboratory findings
Abnormal troponin (>0.05 ng/mL)
Abnormal D-dimer (>0.57 mg/L)
Log-transformed NT-proBNP
Abnormal ferritin (>388 ng/mL)
Abnormal C-reactive protein (>1.0 mg/dL)
Albumin in g/dL

39 (75%)
35 (70%)
5.79 (2.01)
37 (71%)
47 (96%)
2.96 (0.44)

Prehospitalization medications
ARB/ACEi inhibitor
Diuretic
Calcium channel blocker
Beta blocker
Statin

18 (35%)
18 (35%)
13 (25%)
14 (27%)
29 (56%)

COVID-19 treatments
Tocilizumab
Convalescent plasma
Remdesivir
Hydroxychloroquine
Azithromycin
Steroids

26 (50%)
26 (50%)
9 (17%)
33 (63%)
34 (65%)
33 (63%)

Data presented as n (%) or mean (SD). Percentages based
off total number of patients with that variable measured.
ARB/ACEi, angiotensin receptor blocker/angiotensinconverting enzyme inhibitor; BMI, body mass index;
NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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Cardiac complications occurred in 56% of those admitted
to the ICU. Acute ventricular dysfunction (isolated left,
isolated right, or biventricular dysfunction) developed in
40% of patients (3 isolated new or worsening LV systolic
dysfunction, 10 isolated new or worsening RV systolic
dysfunction assessed visually, and 8 with combined LV
and RV systolic dysfunction). New-onset atrial fibrillation
developed in 6 patients. In 1 patient with known severe LV
systolic dysfunction, ventricular tachycardia developed,
necessitating medical intervention. One patient’s ICU
course was complicated by non-ST-elevation myocardial
infarction. No hemodynamically significant valvular
abnormalities were noted in these studies, and no cases of
endocarditis were seen.
On echocardiogram after ICU admission (Table 2),
LVEF was relatively preserved (median: 57%; IQR:

50%, 64%). Yet, 1 in 5 patients (n=11) had new or
worsening LV systolic dysfunction (measured by an
LVEF decrease of >10%). There were 9 patients with
new abnormal LVEF (ie, <50%); of the 4 patients with
known LV dysfunction, 2 had acute worsening of LVEF
by >10%. All were globally hypokinetic. Subclinical
LV dysfunction was prevalent, as both LV GLS and
myocardial global work index were abnormal. Patients
with known prior cardiac disease (40% vs 14% with no
known prior cardiac disease; P=0.03) were more likely
to have new or worsening LV systolic dysfunction and
more abnormal myocardial mechanics (LV GLS, global
myocardial work index) (Table 3).
The most prevalent abnormality on TTE was abnormal
RV size and function. RV enlargement was present in
20 (38%) patients. New or worsening RV dysfunction

Table 2. Echocardiographic Findings in COVID-19 Patients in the Intensive Care Unit (N=52)
Parameter

Total cases with
parameter measured

Mean (IQR) or
parameter-positive n (%)

47
52
38
38
20
30
10
17
20
36
36
52

0.57 (0.5, 0.64)
2.08 (1.82, 2.27)
97.04 (78.07, 122.5)
44.45 (31.14, 53.49)
7.29 (5.70, 8.55)
-16.00 (-17, -14.3)
35.87 (23.76, 49.40)
4.53 (4.01, 6.24)
10.49 (7.22, 14.745)
1515 (1283, 1657.5)
93 (89, 94.5)
11 (21%)

9
9
10
13
44
36
36
52
52
36
52

21.89 (15.5, 23.9)
16.37 (9.35, 17.26)
0.32 (0.18, 0.40)
18.12 (17.39, 22.7)
0.13 (0.102, 0.17)
-19.50 (-23, -15.2)
28 (78%)
18 (35%)
34 (65%)
10 (19%)
20 (38%)

LV echocardiographic parameters
LVEF
Body surface area, m2
End-diastolic volume, mL
End-systolic volume, mL
E’ septal, cm/s
LV GLS, %
Left atrial volume index
Cardiac index
LV filling pressure, E/e’
Global work index, mmHg%
Global work efficiency, %
New or worsening LV dysfunction
RV echocardiographic parameters
Diastolic area, cm2
Systolic area, cm2
Fractional area change
TAPSE, mm
S’ velocity, cm/s
RV GLS, %
Abnormal RV GLS
Visual assessment of RV dysfunction
RV dysfunction (all parameters)a
Pulmonary hypertensionb
RV cavity enlargement
a

Any abnormal value of RV GLS, TAPSE, fractional area change, or S’ velocity.

b

Pulmonary artery systolic pressure of >40 mmHg.

GLS, global longitudinal strain; IQR, interquartile range; LV, left ventricular; LVEF, left ventricular ejection fraction; RV, right
ventricular; TAPSE, tricuspid annular plane systolic excursion.
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Table 3. Echocardiographic Findings in ICU Patients With COVID-19 by Known Status of Prior Cardiac Disease
No known prior
cardiac disease, n=37

Known prior cardiac
disease, n=15

P

LVEF
Body surface area, m2
End-diastolic volume, mL
End-systolic volume, mL
E’ septal, cm/s
LV GLS, %
Left atrial volume index
Cardiac index
LV filling pressure, E/e’
Global work index, mmHg%
Global work efficiency, %
New or worsening LV dysfunction
RV echocardiographic parameters

0.58 (0.55, 0.63)
2.00 (1.80, 2.17)
95.39 (77.99, 114.05)
41.30 (29.83, 50.78)
7.55 (5.77, 8.55)
-16.50 (-18.50, -15)
23.84 (23.21, 43.73)
46.23 (40.15, 62.41)
9.78 (6.47, 11.85)
1605 (1351, 1697)
94 (89, 95)
5 (14%)

0.51 (0.45, 0.65)
2.24 (1.86, 2.39)
117.45 (85.54, 143.4)
56.02 (45.56, 69.2)
6.60 (4.65, 9.28)
-14.25 (-15.25, -9.05)
53.76 (42.31, 57.19)
45.32 (38.37, 62.47)
14.20 (8.75, 20.22)
1276 (756, 1469)
92 (90, 93)
6 (40%)

0.10
0.05
0.22
0.04
0.59
<0.01
0.05
0.99
0.09
0.02
0.37
0.03

Diastolic area, cm2
Systolic area, cm2
TAPSE, mm
S’ velocity, cm/s
RV GLS, %
Visual assessment of RV dysfunction
RV dysfunction (all parameters)
Pulmonary hypertensiona
RV cavity enlargement

19.70 (15.5, 23.92)
12.86 (9.25, 16.81)
17.695 (15.825, 22.37)
0.13 (0.10, 0.17)
-19 (-23, -16)
11 (30%)
23 (62%)
4 (11%)
12 (32%)

23.77 (14.33, 23.9)
19.51 (12.09, 20.68)
22 (18.12, 22.7)
0.13 (0.09, 0.15)
-20 (-22.50, -14)
7 (47%)
11 (73%)
6 (40%)
8 (53%)

0.99
0.12
0.21
0.43
0.69
0.25
0.44
0.02
0.16

LV echocardiographic parameters

Data presented as median (interquartile range) or n (%).
a

Pulmonary artery systolic pressure of >40 mmHg.

GLS, global longitudinal strain; ICU, intensive care unit; LV, left ventricular; LVEF, left ventricular ejection fraction;
RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion.

(assessed qualitatively) was noted in 18 (35%) patients; of
these, 8 (15%) had both LV and RV dysfunction. When
combined with echocardiography-derived parameters
(RV S’ velocity, RV tricuspid annular plane systolic
excursion, RV GLS, RV fractional area change), 34
(65%) cases had some measure of abnormal RV function.
Whether in prone or supine position, additional RV
echocardiographic parameters were obtainable in the
majority of patients (Figure 2). RV GLS was abnormal
in 78% of cases in which RV GLS could be obtained
(n=36; median: -19.50; IQR: -23, -15.2). In patients with
known prior cardiac disease, RV function was worse and
pulmonary artery systolic pressure was higher (Table 3).
Mean ICU stay was 15.5 (SD: 11.8) days, and mean
hospital length of stay was 21.7 (SD: 14.6) days.
Follow-up was available on all patients: overall hospital
mortality was 27% (n=14), 42% (n=22) of patients were
discharged to their home, and 31% (n=16) of patients
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were discharged to a long-term acute care facility (of
whom 7 had a tracheostomy). The 2 patients who received
venovenous extracorporeal membrane oxygenation died
from respiratory failure. Prolonged ventilator time was
associated with worse clinical outcomes. Compared to
those discharged home (Table 4), patients who died or
were discharged to long-term care were more likely to be
older (mean age: 54.9 ± 8.8 years vs 63.6 ± 12.2 years;
P<0.01), have clinical history of atrial fibrillation/atrial
flutter (0% vs 20%; P=0.03), have hypertension (55%
vs 80%; P=0.05), and have known prior cardiac disease
(14% vs 40%, P=0.04).
LV function, as assessed by echocardiography, was not
associated with morbidity and mortality in our small
study. On the RV side, compared to those discharged
home, patients who died or were discharged to long-term
care were more likely to have pulmonary hypertension
(5% vs 30%; P=0.02) and RV cavity enlargement (23%

COVID-19

management and guiding ICU strategy. These imaging
tests were performed by a core group of experienced
cardiac sonographers on state-of-the-art echocardiography
machines using a focused protocol, rather than pointof-care ultrasound or portable ultrasound machines. As
published previously, the mean scan time to complete
this protocol was 15 (SD: 5.6) minutes,9 and none of the
core group contracted the virus. Cardiac sonographers
are at significant risk of COVID-19 exposure due to their
proximity to the patient. Yet, if protected properly with
appropriate personal protective equipment, a focused test
can be performed quickly and with the latest ultrasound
techniques, providing guidance and risk stratification to
ICU teams dealing with the COVID-19 pandemic.9
Figure 2. Ability to perform quantitative
echocardiographic measurements of right ventricular
(RV) function. S' velocity was the most readily
obtained measurement of RV function. RV fractional
area change (FAC) was the least easily obtained.
Abnormal global longitudinal strain (GLS) was the
most frequent abnormality of RV dysfunction.
TAPSE, tricuspid annular plane systolic excursion.

vs 50%; P=0.05). Although not statistically significant,
given low numbers, median RV GLS was more abnormal
in patients who died or were discharged to long-term
care. Abnormal RV GLS was present in 28 of the 36
patients with GLS values (of those 28, 9 died or were
discharged to long-term care). More patients with new
or worsening RV dysfunction also were in the group of
patients who died or were discharged to long-term care.
Finally, in the lowest tertile of RV GLS (ie, ≥-15%),
there was a trend toward longer hospital stay and longer
ICU stay (median hospital stay: 20 [IQR: 13.75, 37.5]
days vs 17.5 [IQR: 10, 28] days; median ICU stay: 14.5
[IQR: 9, 26.25] days vs 9 [IQR: 5.25, 20.75] days).

DISCUSSION

Patients requiring intensive care form a subset of
the COVID-19 pandemic that has a severe and often
multiorgan system response to the virus. In our ICUadmitted population, median ICU and total hospital stays
were long (>2 weeks and >3 weeks, respectively), with
severe respiratory failure and prolonged ventilation. ICU
hospitalizations were not only associated with significant
mortality (27%) but also significant morbidity, as 31% of
patients could not return home after hospital discharge.
Echocardiography plays a crucial role in identifying
cardiovascular complications in patients admitted to the
ICU with COVID-19. Use of advanced echocardiographic
technologies identified clinical and subclinical
abnormalities of heart function, changing clinical

COVID-19

Although the primary etiology of morbidity/
mortality is from respiratory failure, cardiac disease
is not a bystander in critically ill COVID-19 patients.
Cardiovascular complications were very common in
our study and included isolated LV dysfunction, isolated
RV dysfunction, biventricular dysfunction, and atrial
and ventricular arrythmias. Similar findings have been
reported from other centers.11,12 Multiple mechanisms are
implicated in cardiac complications: 1) oxygen-demand
mismatch leading to coronary ischemia, 2) inflammatory
cascade leading to increased ischemic or embolic events,
and 3) direct myocardial injury caused by the virus
entering myocytes.13 Elevated N-terminal pro-B-type
natriuretic peptide, a marker of heart failure, also was
associated with worse clinical outcomes in our patients.
The types of complications we observed were likely a
result of multiple pathways leading to cardiac injury.
Known prior cardiac disease was associated with
increased morbidity and mortality in ICU-admitted
patients with COVID-19, similar to experience in China5
and Italy.6 Known prior cardiac disease, in the Italian
study, was associated with more than double the mortality
in all hospitalizations. In our study, we focused on ICU
patients exclusively and demonstrated that known prior
cardiac disease was associated with higher mortality
and also higher morbidity (ie, more patients with known
cardiac disease required long-term acute care, even if
they survived hospitalization). This is particularly true
of left-sided disease, as LV dysfunction at baseline was
associated with acute worsening of LVEF during ICU
hospitalization.
The most common cardiac complication in our study
was RV enlargement and dysfunction. In contrast to leftsided disease, this complication was independent of a
history of known prior cardiac disease. This is consistent
with a prior study, in which RV dilation was the only
echocardiographic finding to prognosticate mortality in
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Table 4. Comparison of ICU Patients Discharged Home With Those Having Significant Morbidity and Mortality
(Death or Discharged to LTAC)
Variable
Age in years
Race/Ethnicity
Hispanic
Non-Hispanic White
Black
Other
Male sex
Tobacco abuse
Obesity (BMI of >30 kg/m2)
Atrial fibrillation/Atrial flutter
COPD
Coronary artery disease
Diabetes
Dyslipidemia
Heart failure
Hypertension
Cancer
Known prior cardiac disease
Log-transformed NT-proBNP
Time on ventilator in days

Alive, discharged home
n=22
54.9 (8.8)

Dead or in LTAC
n=30
63.6 (12.2)

P
<0.01

9 (41%)
5 (23%)
4 (18%)
4 (18%)
11 (50%)
5 (24%)
14 (67%)
0 (0%)
1 (5%)
2 (9%)
8 (36%)
12 (55%)
2 (9%)
12 (55%)
2 (9%)
3 (14%)
91 (44.8, 360.8)
7 (5.5, 9)

9 (30%)
10 (33%)
9 (30%)
2 (7%)
20 (67%)
17 (56%)
13 (52%)
6 (20%)
4 (13%)
7 (23%)
11 (37%)
23 (77%)
9 (30%)
24 (80%)
8 (27%)
12 (40%)
673.5 (93.3, 2774.3)
15 (6.5, 27)

0.38
0.23
0.11
0.31
0.03
0.29
0.18
0.98
0.09
0.07
0.05
0.11
0.04
0.03
0.03

0.56 (0.52, 0.6)
2.02 (1.80, 2.22)
89.8 (74.06, 122.5)
41.27 (27.79, 53.49)
7.58 (6.20, 8.39)
-16 (-17, -14.50)
29.43 (23.84, 53.76)
47.62 (37.62, 57.63)
10.77 (8.72, 15.52)
1623.5 (1341.5, 1769)
94 (91.5, 95.5)
5 (23%)

0.59 (0.47, 0.65)
2.08 (1.86, 2.27)
109.4 (87.68, 128.7)
48.9 (37.11, 58.83)
6.60 (5.32, 10.12)
-15 (-17, -14)
42.31 (23.21, 49.40)
45.32 (42.71, 62.47)
10.19 (6.55, 14.58)
1433.5 (1267.5, 1605.5)
90.5 (88, 94)
6 (20%)

0.48
0.59
0.18
0.26
0.94
0.36
0.73
0.56
0.59
0.18
0.07
0.81

17.5 (15.5, 23.9)
9.35 (9.25, 20.68)
0.40 (0.13, 0.47)
21 (18.12, 25.43)
0.12 (0.10, 0.15)
-20 (-22, -15)
13 (59%)
1 (5%)
5 (23%)
7 (32%)

22.83 (14.33, 23.92)
16.59 (12.09, 17.26)
0.32 (0.18, 0.37)
18 (16.70, 22.35)
0.14 (0.10, 0.17)
19 (-23, -15.90)
21 (70%)
9 (30%)
15 (50%)
11 (37%)

0.80
0.80
0.57
0.30
0.49
0.97
0.41
0.02
0.05
0.72

LV echocardiographic parameters
LVEF
Body surface area, m2
End-diastolic volume, mL
End-systolic volume, mL
E’ septal, cm/s
LV GLS, %
Left atrial volume index
Cardiac index
LV filling pressure, E/e’
Global work index, mmHg%
Global work efficiency, %
New or worsening LV dysfunction
RV echocardiographic parameters
Diastolic area, cm2
Systolic area, cm2
Fractional area change
TAPSE, mm
S’ velocity, cm/s
RV GLS, %
RV dysfunction (all parameters)a
Pulmonary hypertensionb
RV cavity enlargement
Visual assessment of RV dysfunction

Data presented as n (%), mean (standard deviation), or median (interquartile range).
a

Any abnormal value of RV GLS, TAPSE, fractional area change, or S’ velocity.

b

Pulmonary artery systolic pressure of ≥40 mmHg.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; GLS, global longitudinal strain; ICU, intensive care
unit; LTAC, long-term acute care facility; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion.
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hospitalized patients with COVID-19 (odds ratio: 4.5,
95% CI: 1.5–13.7).8 In our study, RV enlargement was
associated with both mortality and significant morbidity
in those who were critically ill. In the Wuhan, China,
study, bedside echocardiography was performed on
patients with COVID-19, up to a week into admission,
and detailed echocardiographic measurements including
myocardial mechanics were performed.7 Of note and in
contrast to our study, patients with known prior cardiac
disease were excluded. A threshold RV GLS of -23% was
observed as a cutoff value, and values greater than -23%
were associated with higher mortality.7 We used this same
value in our study and noted that abnormal RV GLS was
present in 28 of the 36 patients with recorded GLS values.
In a New York series, portable ultrasound was used and
RV dilation was defined semiquantitatively.8 As in the
Wuhan study, we chose not to use portable ultrasound.
Instead, we used latest-generation echocardiography
machines; therefore, multiple abnormalities of RV
function could be identified, including cases that would
be missed if only visual assessment of RV function was
performed. If only point-of-care or limited portable
ultrasound machines were used, RV dysfunction would
have been detected in just 18 patients. Visual assessment
of RV function is usually noted by the echocardiographer
observing reduced RV radial function, seen in apical
and subcostal views; however, using state-of-the-art
echocardiographic technology, RV dysfunction can be
assessed with multiple well-validated assessments of
RV function. We therefore noted RV dysfunction in the
majority (65%) of ICU patients with COVID-19.
RV function has been implicated in prior studies of
acute respiratory distress syndrome as a contributor
to morbidity,14 and a similar mechanism of hypoxic
vasoconstriction to that seen in acute respiratory distress
syndrome may also be seen in COVID-19. SARSCoV-2 may directly affect RV myocytes, leading to
RV myocarditis. Finally, COVID-19 is associated
with thromboembolic complications, and microscopic
pulmonary emboli may contribute to RV dysfunction.
Szekely et al noted that worsening RV dysfunction was
associated with clinical deterioration in hospitalized
COVID-19 patients.15 Further research is needed to
evaluate mechanisms of RV dilation and dysfunction as
well as treatment strategies.
This identification of pulmonary hypertension and
RV dysfunction by echocardiography was crucial
in guiding ICU practice. When RV dysfunction was
identified in our ICU, single or multiple strategies were
employed to minimize mortality from RV dysfunction
— afterload reduction with nitric oxide, dobutamine for
ionotropic support, and even more conservative fluid
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management. Epoprostenol was not used to minimize
virus aerosolization that could occur from breaking
the ventilator circuit. Positive end-expiratory pressure
ventilation also was limited. Although beyond the scope
of this study, future studies could evaluate the benefit of
anticoagulation on RV function in hospitalized patients
with COVID-19.
Limitations

This is a single-center study evaluating echocardiographic
variables in patients with COVID-19 illness who required
ICU admission. This study is limited to only those patients
with COVID-19 in whom the primary provider clinically
assessed a need for an echocardiogram; however, as part
of routine clinical care, most patients admitted to the ICU
did receive limited TTE. This study is also limited by
the fact that patients without a previous echocardiogram
available were categorized as no known prior cardiac
disease but may in fact have had prior cardiac disease
that was not diagnosed.

CONCLUSIONS

ICU admission for COVID-19 is associated with
significant morbidity and mortality in an ethnically
diverse population. Echocardiography has an additive
role in identifying complications and highlighting
patients who require further care. The most common
echocardiographic abnormality is right ventricular
dysfunction, which can be assessed more accurately using
state-of-the-art echocardiography. Known prior cardiac
disease, relatively older age, atrial fibrillation/atrial
flutter, RV enlargement, and pulmonary hypertension are
associated with worse outcomes.
Patient-Friendly Recap
• Patients diagnosed with COVID-19 who are admitted
to the intensive care unit (ICU) are at significant risk
of dying or requiring long-term acute care.
• Cardiovascular complications are common
in these patients and often identified using
echocardiographic imaging.
• In addition to having a history of prior cardiac
disease, the presence of pulmonary hypertension,
atrial fibrillation/flutter, or enlarged right ventricle as
measured by echocardiography increases the risk
of poor outcomes for those hospitalized in the ICU
with COVID-19.
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